Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics Inc. (MYGN) is a leader in molecular diagnostics and precision medicine, developing genetic tests that inform critical healthcare decisions across oncology, hereditary cancer risk assessment, and reproductive health. This news hub provides investors and healthcare professionals with timely updates on the company's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases and third-party analysis covering MYGN's financial results, product innovations, and clinical collaborations. Our curated collection includes updates on diagnostic test approvals, partnership announcements with healthcare systems, and developments in personalized treatment solutions. All content is organized chronologically for efficient tracking of the company's progress in genetic testing technologies.
Key areas of focus include updates to Myriad's hereditary cancer screening panels, advancements in tumor profiling accuracy, and expansions in pharmacogenomic testing capabilities. The page also tracks regulatory submissions and peer-reviewed study publications validating the company's diagnostic approaches.
Bookmark this page for streamlined access to Myriad Genetics' latest developments in DNA-based health solutions. Check regularly for updates on how MYGN continues shaping precision medicine landscape through innovative diagnostic technologies and evidence-based clinical tools.
Myriad Genetics (NASDAQ: MYGN), Clairity, and MagView announced a collaboration on Nov 25, 2025 to deliver the first integrated platform combining genotype and AI-derived phenotype for breast cancer risk assessment.
The integration links Myriad’s MyRisk with RiskScore hereditary cancer test, Clairity Breast (the FDA-authorized AI mammogram risk estimator), and MagView’s Luminary Risk workflow to provide clinicians a unified, actionable view of five-year breast cancer risk from routine mammograms and genetics.
The partners say the platform aims to identify more women at elevated risk and support earlier, personalized interventions while preserving clinical workflow efficiency.
Myriad Genetics (NASDAQ: MYGN) said its management will participate in two investor healthcare conferences in late 2025. Wolfe Research Healthcare Conference — fireside chat on Nov. 18, 2025 at 1:20 pm ET. Piper Sandler Healthcare Conference — fireside chat on Dec. 2, 2025 at 12:00 pm ET. Both presentations will be available via live audio webcasts in the investor information section at investor.myriad.com.
Myriad Genetics (NASDAQ: MYGN) expanded its MyRisk® Hereditary Cancer Test on Nov 10, 2025 to include genes referenced in NCCN and ASCO guidelines.
The updated MyRisk panel now includes 63 genes covering more than 11 cancer types, and the company says it includes 100% of genes strongly recommended by national oncology guidelines to support treatment decisions, surveillance planning, and family risk assessment.
Results are available via paper requisition, the Myriad patient portal and multiple EMR platforms including EPIC.
Myriad Genetics (NASDAQ: MYGN) will present 11 new research studies at the National Society of Genetic Counselors 44th Annual Conference on Nov. 7–8, 2025, highlighting oncology and reproductive genetic testing advances.
Featured products include MyRisk Hereditary Cancer Test, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, and Foresight Carrier Screen. Myriad will exhibit at booth #317 and share poster presentations on topics such as RNA analysis for VUS interpretation, fetal fraction amplification for early cfDNA screening, prenatal cfDNA detecting maternal colorectal cancer, automated FXN repeat detection, and genetics education and recontact workflows.
Myriad Genetics (NASDAQ: MYGN) reported third quarter 2025 results: revenue $205.7M (down 4% YoY, flat ex‑$8.1M headwinds), gross margin 69.9%, GAAP net loss $27.4M (loss per share $0.29) and adjusted EPS $0.00. Third quarter adjusted EBITDA was $10.3M and test volumes rose to 386,000 (+3% YoY), led by hereditary cancer volume +11%.
The company entered a strategic collaboration with SOPHiA GENETICS for liquid biopsy CDx development, closed a $200M term loan in July, and ended the quarter with $145.4M cash. Myriad reiterated full‑year 2025 guidance: Revenue $818–$828M, gross margin 69.5%–70.0%, adjusted EBITDA $27–$33M, adjusted EPS $(0.02)–$0.02.
Myriad Genetics (NASDAQ: MYGN) reported a post-hoc analysis of the PRIME study showing GeneSight-informed treatment produced faster remission and response in major depressive disorder.
The PRIME trial enrolled 1,944 U.S. Veterans. The analysis, published Oct 30, 2025 in Frontiers in Pharmacology, found GeneSight patients were 27% more likely to achieve remission and 21% more likely to experience response at any time during the 24-week study, with benefits persisting through six months. Myriad plans to submit these data to payers to support access to GeneSight.
Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2025 financial results on November 3, 2025 after market close and will host an earnings conference call the same day at 4:30 PM ET. Management will provide a financial overview and business update for Q3 2025.
A live webcast will be available on Myriad’s Investor Relations website at investor.myriad.com. Telephone participants must register to receive a dial-in number and unique PIN. An archived webcast will be posted at investor.myriad.com following the call.
Myriad Genetics (NASDAQ: MYGN) announced on October 14, 2025 that it added the F8 and FXN genes to the Foresight® Carrier Screen Universal Plus Panel. The company said the additions meet its clinical-selection criteria and that testing is processed in its state-of-the-art facility.
The update makes the Foresight Carrier Screen fully compliant with ACMG recommendations. The release notes F8's link to hemophilia A and FXN's link to Friedreich's ataxia and references the FDA's 2023 approval of omaveloxolone for FA in patients aged 16+.
Myriad Genetics (Nasdaq: MYGN) and SOPHiA GENETICS (Nasdaq: SOPH) have announced a strategic collaboration to develop a global liquid biopsy companion diagnostic (CDx) test. The partnership combines Myriad's U.S. laboratory capabilities with SOPHiA GENETICS' network of over 800 institutions across 70+ countries.
The initial focus will be on MSK-ACCESS® powered with SOPHiA DDM™, a liquid biopsy test developed with Memorial Sloan Kettering Cancer Center that detects genomic alterations from blood samples using ctDNA analysis. Myriad will handle U.S. regulatory submissions, while SOPHiA GENETICS will manage international regulatory processes.
Myriad Genetics (NASDAQ: MYGN) announced the publication of clinical data for its Precise MRD test in The Lancet Oncology. The study focused on patients with oligometastatic clear-cell renal cell carcinoma (ccRCC) and demonstrated significant results in detecting circulating tumor DNA (ctDNA).
The Phase 2 trial revealed that 94% of patients had ctDNA levels below 100 ppm at baseline. Patients testing negative with Precise MRD maintained metastasis-directed therapy for a median of 54 months, compared to 27 months for ctDNA-positive patients. Notably, ctDNA-negative patients showed strong survival rates of 94% at two years and 87% at three years.
FAQ
What is the current stock price of Myriad Genetics (MYGN)?
What is the market cap of Myriad Genetics (MYGN)?
